What Researchers Did
Researchers reviewed recent aspects of diagnostics, differential diagnostics, and evidence for systemic and local therapy of idiopathic sudden sensorineural hearing loss (ISSHL).
What They Found
They found that intralabyrinthine schwannomas (ILS) are likely significantly underestimated due to insufficient MRI techniques, emphasizing the need for specific MRI requests. The quality of evidence for ISSHL therapy, including corticosteroids, remains unsatisfying, though a national multicenter trial is currently underway in Germany to investigate high-dose corticosteroids.
What This Means for Canadian Patients
Canadian patients experiencing sudden hearing loss should ensure their diagnostic imaging specifically evaluates for intralabyrinthine tumors. Treatment options for ISSHL, particularly corticosteroid use, require further high-quality research to establish clear efficacy and safety.
Canadian Relevance
This review has no direct Canadian connection as it focuses on general diagnostic and therapeutic aspects of ISSHL.
Study Limitations
A significant limitation highlighted is the overall unsatisfying quality of existing evidence for ISSHL therapies, making definitive treatment recommendations challenging.